NCT07437963 2026-03-19
Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse
National Cancer Institute (NCI)
Phase 1/2 Not yet recruiting
Clinical Trials
17 trialsNCT03126916 2026-02-27
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
Children's Oncology Group
Phase 3 Recruiting
NCT07375563 2026-01-29
NB-NK-2026
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Phase 3 Recruiting
NCT01175356 2026-01-23
Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin
Children's Oncology Group
Phase 1 Completed
NCT04040088 2026-01-08
An Investigational Scan (68Ga-DOTATATE PET/CT) in Diagnosing Pediatric Metastatic Neuroendocrine Tumors
Mayo Clinic
Phase EARLY_PHASE1 Active not recruiting
NCT06858501 2025-12-31
Comparing 123I-MIBG and 18F-MFBG Imaging in Patients With Newly Diagnosed, High Risk Neuroblastoma
Children's Oncology Group
Phase 2 Not yet recruiting
NCT02112617 2025-12-30
Phase II Study of Proton Radiation Therapy for Neuroblastoma
Massachusetts General Hospital
Phase NA Recruiting
NCT02176967 2025-12-22
Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma
Children's Oncology Group
Phase 3 Active not recruiting
NCT00904241 2025-11-13
Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma
Children's Oncology Group
Active not recruiting
NCT04385277 2025-10-27
Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL)
Children's Oncology Group
Phase 2 Active not recruiting
NCT03786783 2025-10-09
Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06798532 2025-09-12
AKA-NBL
Assistance Publique - Hôpitaux de Paris
Not yet recruiting
NCT02311621 2025-05-28
Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01
Seattle Children's Hospital
Phase 1 Active not recruiting
NCT03088020 2024-08-09
International Congenital Central Hypoventilation Syndrome (CCHS) Registry and CCHS SHARE
Ann & Robert H Lurie Children's Hospital of Chicago
Recruiting
NCT01798004 2024-07-15
Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma
Children's Oncology Group
Phase 1 Completed
NCT06071897 2023-10-10
Induction Chemoimmunotherapy for Patients With High-risk Neuroblastoma
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Phase 3 Recruiting
NCT01767194 2022-10-24
Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma
National Cancer Institute (NCI)
Phase 2 Completed